Clinical Trial Update: A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy [Phase 3]

View source ↗

Summary

Phase 3 trial of TEV-50717 in cerebral palsy with dyskinetic movements was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Palsy
• Dyskinetic Cerebral Palsy

Drugs mentioned

• TEV-50717

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Cerebral Palsy, Dyskinetic | Phase 3 | Status: TERMINATED | Results posted: 2024-04-22